---
id: chylothorax
condition: Chylothorax
aliases: [chylous effusion, thoracic duct injury, chylous pleural effusion, chyle leak]
icd10: [J94.0]
esi: 3
time_to_harm: "< 48 hours (nutritional/immune depletion if massive)"
category: respiratory
track: tier1
sources:
  - type: review
    ref: "McGrath EE, et al. Diagnosis of Pleural Effusion: A Systematic Approach. Am J Crit Care. 2011;20(2):119-127."
  - type: review
    ref: "Doerr CH, et al. Etiology of Chylothorax in 203 Patients. Mayo Clin Proc. 2005;80(7):867-870."
  - type: review
    ref: "Rudrappa M, Paul M. Chylothorax. StatPearls. 2024."
last_updated: "2026-03-01"
compiled_by: agent
risk_tier: B
validation:
  automated_consistency_check: null
  dose_range_validator: null
  unit_normalization_check: null
  cross_file_consistency_check: null
  citation_presence_check: null
  duplicate_content_check: null
  outlier_detection_flag: clear
  schema_version: "2.0"
  provenance_links: []
---
# Chylothorax

## Recognition

**Presentation:**
- Dyspnea (large effusion causing lung compression)
- Unilateral effusion — left-sided (60-70%) due to thoracic duct anatomy
- No pleuritic chest pain (chyle is non-irritating)
- Milky or opalescent pleural fluid (classic but not always present; may be serous if fasting)
- Signs of nutritional depletion if chronic: weight loss, lymphopenia, hypoalbuminemia
- Immunosuppression from lymphocyte loss (T-cell depletion)

**Etiologies:**
- **Surgical/traumatic (most common):** Post-thoracic surgery (esophagectomy, cardiac surgery, lung resection), central line placement, penetrating/blunt thoracic trauma
- **Non-traumatic:** Lymphoma (most common non-surgical cause), other malignancies, sarcoidosis, lymphangioleiomyomatosis (LAM), superior vena cava thrombosis, cirrhosis, congenital duct abnormalities

**Diagnostic criteria (pleural fluid):**
- Triglycerides > 110 mg/dL = chylothorax confirmed
- Triglycerides < 50 mg/dL = chylothorax excluded
- Triglycerides 50-110 mg/dL = check for chylomicrons (lipoprotein electrophoresis)
- Lymphocyte-predominant fluid (> 80%)

## Critical Actions

| Action | Target |
|---|---|
| Therapeutic thoracentesis (if symptomatic) | < 2 hours |
| Pleural fluid triglycerides | With initial thoracentesis |
| Nutritional assessment | < 12 hours |
| Identify etiology | < 48 hours |

1. **Therapeutic thoracentesis or tube thoracostomy** for respiratory compromise
2. **Send pleural fluid for triglycerides, cholesterol, cell count, protein, LDH, cytology**
3. **NPO or medium-chain triglyceride (MCT) diet** — MCTs are absorbed directly into portal circulation, bypassing the thoracic duct, reducing chyle flow
4. **Total parenteral nutrition (TPN)** if high-output chylothorax (> 1 L/day) — complete gut rest minimizes chyle production
5. **CT chest/abdomen/pelvis** — identify underlying malignancy, lymphadenopathy, thoracic duct injury
6. **Thoracic surgery and/or interventional radiology consultation** for refractory chylothorax

## Differential Diagnosis

- **Pseudochylothorax (cholesterol effusion)** — chronic effusion with cholesterol crystals; cholesterol > 200 mg/dL, triglycerides < 110. Seen in chronic TB or rheumatoid pleurisy.
- **Empyema** — purulent, high WBC; may appear milky. Triglycerides distinguish.
- **Malignant effusion** — cytology positive; may coexist with chylothorax (lymphoma)
- **Hemothorax** — bloody fluid; hematocrit > 50% of serum
- **Hepatic hydrothorax** — transudative, right-sided, associated with cirrhosis/ascites

## Workup

- **Pleural fluid analysis:**
  - Triglycerides > 110 mg/dL confirms chylothorax
  - Cholesterol (low in chylothorax, high in pseudochylothorax)
  - Cell count (lymphocyte predominant > 80%)
  - Protein, LDH (Light's criteria — chylothorax is typically exudative)
  - Cytology (rule out malignancy)
  - Chylomicrons on lipoprotein electrophoresis (if triglycerides 50-110)
- **CT chest/abdomen/pelvis with contrast:** Lymphadenopathy, malignancy, thoracic duct course
- **Lymphangiography or MR lymphangiography:** Identify site of thoracic duct leak (if surgical intervention planned)
- **Labs:** CBC (lymphopenia), albumin (low from protein loss), prealbumin, immunoglobulin levels, total protein, lipid panel
- **PET-CT:** If malignancy suspected (lymphoma workup)

## Treatment

### Conservative Management (First-Line)
- **NPO + TPN:** Complete bowel rest reduces chyle production by 50-80%; start within 24-48 hours for high-output chylothorax
- **MCT diet:** Substitute for TPN in low-output chylothorax (< 500 mL/day); MCTs bypass lymphatic absorption
- **Octreotide 100 mcg SC TID or continuous infusion 50 mcg/hr** — reduces chyle flow via splanchnic vasoconstriction and GI secretion reduction
- **Chest tube drainage** — continuous or intermittent, to allow lung re-expansion and monitor output
- **Nutritional support:** Replace protein (albumin infusion if < 2.5), immunoglobulins if severely depleted

### Interventional Procedures
- **Thoracic duct embolization (TDE):** Percutaneous lymphangiography-guided embolization; success rate 70-80%
- **Thoracic duct ligation:** Surgical (VATS or thoracotomy) ligation of the thoracic duct; for failure of conservative management after 7-14 days
- **Pleurodesis:** Chemical pleurodesis with talc for recurrent malignant chylothorax
- **PleurX catheter:** Indwelling pleural catheter for palliative drainage in malignancy-related chylothorax

### Indications for Surgical Intervention
- Output > 1 L/day for > 5 days despite conservative management
- Output > 1.5 L/day for > 3 days
- Nutritional depletion (albumin < 2.0, weight loss > 5%)
- Post-surgical chylothorax not responding to 2 weeks of conservative treatment

## Disposition

- **Inpatient admission:** All new chylothorax for drainage, dietary modification, and etiologic workup
- **ICU:** If respiratory failure, massive chylothorax with hemodynamic compromise, or severe malnutrition
- **Thoracic surgery consultation:** High-output chylothorax, failure of conservative management
- **Oncology referral:** If malignancy identified (lymphoma is the most common non-traumatic cause)
- **Outpatient management:** Resolved low-output chylothorax with MCT diet, follow-up imaging

## Pitfalls

1. **Sending pleural fluid for standard analysis without triglycerides.** Chylothorax is diagnosed by triglyceride level (> 110 mg/dL). If triglycerides are not ordered, the milky appearance may be attributed to empyema or high protein content, and the true diagnosis is missed.

2. **Confusing chylothorax with pseudochylothorax.** Pseudochylothorax (cholesterol effusion) has high cholesterol (> 200 mg/dL) but LOW triglycerides (< 110 mg/dL) and is associated with chronic effusions (TB, rheumatoid). True chylothorax has high triglycerides and low cholesterol. Treatment differs.

3. **Not recognizing the immunosuppressive consequences of chylothorax.** Chyle contains large numbers of lymphocytes (predominantly T cells) and immunoglobulins. Ongoing chyle loss leads to functional immunodeficiency, increasing infection risk. Quantify lymphocyte count and immunoglobulin levels, and consider supplemental IVIG in severe depletion.

4. **Delaying NPO/TPN in high-output chylothorax.** Continued oral intake maintains chyle production. High-output leaks (> 1 L/day) should be placed on TPN within 24-48 hours. This is the single most impactful non-procedural intervention.
